Eli Lilly and Company (LLY)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE
Market Cap: $1.29T
Last updated: Nov 17, 2026 at 11:06 AM ET
Eli Lilly and Company (LLY) Stock Forecast
Analysts expect Eli Lilly and Company (LLY) to earn $35.39 per share in the fiscal year ending Dec 31, 2026, on revenue of $91.67B. Of 31 analysts, 26 rate the stock Buy or Strong Buy, 3 Hold and 2 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is $50.64.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 31 ratings average 2.06, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 84% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 6 | 19.4% |
| Buy | 20 | 64.5% |
| Hold | 3 | 9.7% |
| Sell | 1 | 3.2% |
| Strong Sell | 1 | 3.2% |
- Consensus
- Buy
- Total analysts
- 31
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 43.1% and revenue estimates rise 16.2%.
- Fiscal year ending Dec 31, 2026
- $35.39
- EPS consensus, revenue $91.67B
- Fiscal year ending Dec 31, 2027
- $50.64
- EPS consensus, revenue $106.49B
- Next report
- Feb 2, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $35.39 | $32.68 to $36.28 | 26 | $91.67B | $88.56B to $93.00B | 25 |
| Dec 31, 2027 | $50.64 | $41.28 to $59.81 | 28 | $106.49B | $93.90B to $114.30B | 29 |
Quarterly Estimates
The EPS consensus falls from $11.28 for the quarter ending Dec 31, 2026 to $10.94 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $11.28 | $10.15 to $13.04 | 21 | $24.84B | $23.34B to $27.10B | 18 |
| Mar 31, 2027 | $10.94 | $10.31 to $11.63 | 6 | $23.55B | $22.64B to $24.60B | 5 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 20 upward and 1 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2027 | 18 | 1 |
| Quarter ending Mar 31, 2027 | 2 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has fallen 3.1% from $36.51.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $35.39 | $35.35 | $35.77 | $36.71 | $36.51 | -3.1% |
| Fiscal year ending Dec 31, 2027 | $50.64 | $50.15 | $47.64 | $47.24 | $46.63 | +8.6% |
| Quarter ending Mar 31, 2027 | $10.94 | $10.46 | $9.96 | $9.73 | $9.94 | +10.1% |
Frequently Asked Questions About LLY
What is the LLY stock forecast?
Consensus analyst estimates put Eli Lilly and Company's EPS at $35.39 for the fiscal year ending Dec 31, 2026, on revenue of $91.67B. The consensus rating from 31 analysts is Buy.
How do analysts rate LLY stock?
Of 31 analysts covering Eli Lilly and Company, 6 rate it Strong Buy, 20 Buy, 3 Hold, 1 Sell and 1 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from LLY next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $35.39, with estimates from $32.68 to $36.28 from 26 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $50.64, with estimates from $41.28 to $59.81 from 28 analysts.
What revenue do analysts expect from Eli Lilly and Company next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $91.67B, with estimates from $88.56B to $93.00B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $106.49B, with estimates from $93.90B to $114.30B.
How many analysts cover LLY?
31 analysts rate Eli Lilly and Company stock, and 26 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
LLY pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts